Is Rucaparib a targeted drug?

Rucaparib is a targeted cancer drug. It is also known asRubraca. This is a treatment for many different cancer types, including certain hereditary breast and ovarian and prostate cancers linked to the BRCA1 and BRCA2 genes. If a patient responds to platinum-based chemotherapy, they may be given rucapanib after treatment. This is called maintenance treatment. Platinum chemotherapy may include the drugs cisplatin and carboplatin.

Rucapanib is a targeted drug called a PARP inhibitor. PARP is a protein that helps damaged cells repair themselves. Rucapanib stops PARP from working. Some cancer cells rely on PARP to keep their DNA healthy. This includes cancer cells with changes in the BRCA gene. Therefore, when rucapanib prevents PARP from repairing DNA damage, cancer cells die. This type of treatment that targets specific molecules or signaling pathways is called targeted therapy because it targets specific abnormalities in tumor cells without causing much damage to normal cells.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).